Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders - Quiz - MDSpire

Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders

  • By

  • Lorne Schweitzer

  • Stéphanie Thiant

  • Cynthia Thérien

  • Martin Giroux

  • Sylvie Lachance

  • Isabelle Fleury

  • Julie Orio

  • Cédric Carli

  • Gabrielle Boudreau

  • Julien Patenaude

  • Camille Tremblay-Laganière

  • Lynne Senécal

  • Simon F Dufresne

  • Luigina Mollica

  • Suzon Collette

  • Guy Sauvageau

  • Thomas Kiss

  • Sandra Cohen

  • Léa Bernard

  • Nadia Bambace

  • Olivier Veilleux

  • Imran Ahmad

  • Jean Roy

  • Lambert Busque

  • Michel Duval

  • Henrique Bittencourt

  • Pierre Teira

  • Caroline Lamarche

  • Denis-Claude Roy

  • Jean-Sébastien Delisle

  • January 20, 2026

  • 0 min

Share

Original Source(s)

Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders

  • by Lorne Schweitzer, Stéphanie Thiant, Cynthia Thérien, Martin Giroux, Sylvie Lachance, Isabelle Fleury, Julie Orio, Cédric Carli, Gabrielle Boudreau, Julien Patenaude, Camille Tremblay-Laganière, Lynne Senécal, Simon F Dufresne, Luigina Mollica, Suzon Collette, Guy Sauvageau, Thomas Kiss, Sandra Cohen, Léa Bernard, Nadia Bambace, Olivier Veilleux, Imran Ahmad, Jean Roy, Lambert Busque, Michel Duval, Henrique Bittencourt, Pierre Teira, Caroline Lamarche, Denis-Claude Roy, Jean-Sébastien Delisle

  • January 20, 2026

Related Content

Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report from the Saudi Society of Blood and Marrow Transplantation (SSBMT)

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.